Clinical Trials
117 trialsNCT06820463 2026-05-27
AndroMETa-CRC
AbbVie
Phase 2 Recruiting
NCT05576896 2026-05-26
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Recruiting
NCT04787341 2026-05-20
PARERE
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT07094204 2026-05-18
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT05863195 2026-05-15
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05694936 2026-05-08
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group
Phase 2 Active not recruiting
NCT05198934 2026-04-27
CodeBreak300
Amgen
Phase 3 Completed
NCT06252649 2026-04-24
CodeBreaK 301
Amgen
Phase 3 Recruiting
NCT07543744 2026-04-22
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
R-Pharm
Phase 1 Recruiting
NCT05786924 2026-04-21
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Phase 1/2 Recruiting
NCT02394834 2026-04-13
An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer
Takeda
Active not recruiting
NCT05845450 2026-03-12
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT07318389 2026-02-27
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT07094113 2026-02-12
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Amgen
Phase 1 Recruiting
NCT03693807 2026-02-06
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04587128 2026-02-05
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT06268015 2026-02-05
BBOpCo
Duke University
Phase 2 Active not recruiting
NCT03087071 2026-01-12
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03366155 2026-01-08
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03983993 2026-01-05
NIPAVect
Emory University
Phase 2 Active not recruiting
NCT06714357 2025-12-17
VICTORIA
National Cancer Institute, Naples
Phase 2 Recruiting
NCT06245356 2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2 Recruiting
NCT01312857 2025-10-09
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02885753 2025-07-09
OSCAR
Federation Francophone de Cancerologie Digestive
Phase 3 Recruiting
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03584711 2025-06-29
OPTIPRIME
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT06978400 2025-05-18
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
Phase 2 Recruiting
NCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT06194877 2025-04-20
A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
MapKure, LLC
Phase 1 Terminated
NCT02980510 2025-02-20
PANIRINOX
UNICANCER
Phase 2 Active not recruiting
NCT02162563 2025-02-06
CAIRO5
Dutch Colorectal Cancer Group
Phase 3 Completed
NCT03635021 2024-10-21
CR-SEQUENCE
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 3 Active not recruiting
NCT04117945 2024-09-27
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT03263429 2024-08-30
Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Completed
NCT05084859 2024-08-09
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Biosplice Therapeutics, Inc.
Phase 1 Terminated
NCT00788957 2024-08-07
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
NantBioScience, Inc.
Phase 1/2 Completed
NCT06509126 2024-07-19
IMPROVE-2
National Cancer Institute, Naples
Phase 3 Recruiting
NCT00891930 2024-07-17
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
NantBioScience, Inc.
Phase 2 Completed
NCT03992456 2024-05-21
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Unknown
NCT03043950 2024-04-24
VALIDATE
iOMEDICO AG
Completed
NCT06226857 2024-01-29
CRC01
City Clinical Oncology Hospital No 1
Phase 3 Recruiting
NCT01776307 2023-11-15
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Sumitomo Pharma America, Inc.
Phase 2 Completed
NCT02394795 2023-11-01
PARADIGM
Takeda
Phase 3 Completed
NCT01591421 2023-08-04
P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT01328171 2023-06-15
VOLFI
AIO-Studien-gGmbH
Phase 2 Completed
NCT01991873 2023-06-15
PanaMa
AIO-Studien-gGmbH
Phase 2 Completed
NCT01801904 2023-03-24
PACER
National Cancer Institute, Naples
Phase 2 Unknown
NCT03231722 2023-01-05
TRIPLETE
Gruppo Oncologico del Nord-Ovest
Phase 3 Completed
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT01732783 2022-11-08
Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients
Amgen
Completed